Atossa Therapeutics (FRA:YAG2) Common Stock : €21.00 Mil (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Atossa Therapeutics Common Stock?

Atossa Therapeutics's quarterly common stock declined from Sep. 2023 (€21.36 Mil) to Dec. 2023 (€20.90 Mil) but then increased from Dec. 2023 (€20.90 Mil) to Mar. 2024 (€21.00 Mil).

Atossa Therapeutics's annual common stock increased from Dec. 2021 (€20.17 Mil) to Dec. 2022 (€21.52 Mil) but then declined from Dec. 2022 (€21.52 Mil) to Dec. 2023 (€20.90 Mil).

Atossa Therapeutics Common Stock Historical Data

The historical data trend for Atossa Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atossa Therapeutics Common Stock Chart

Atossa Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

1.48

7.04

20.17

21.52

20.90

Atossa Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Common Stock	Get a 7-Day Free Trial															21.29	21.04	21.36	20.90	21.00

Atossa Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Atossa Therapeutics (FRA:YAG2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atossa Therapeutics Inc (FRA:YAG2) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

ATOS:USA ATOS:Mexico YAG2:Germany

Address

107 Spring Street, Seattle, WA, USA, 98104

Website

https://www.atossatherapeutics.com

Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company developing proprietary innovative medicines in areas of significant unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Atossa Therapeutics (FRA:YAG2) Headlines

No Headlines